

CORRECTION

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt¹ · Kim A. Papp² · Christopher E. M. Griffiths³ · Luis Puig⁴ · Jamie Weisman⁵ · Yves Dutronc⁶ · Lisa Farmer Kerr⁶ · Dapo Ilo⁶ · Lotus Mallbris⁶ · Matthias Augustin⁷

Published online: 29 March 2018
© The Author(s) 2018

Correction to: *Am J Clin Dermatol* (2017) 18:273–280
<https://doi.org/10.1007/s40257-016-0246-9>

The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt, Kim A. Papp, Christopher E. M. Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin was originally published Online First without open access. After publication in volume 18, issue 2, pages 273–280 the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2017

and the article is forthwith distributed under the terms of the Creative Commons Attribution Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40257-016-0246-9>.

✉ Andrew Blauvelt
ablauvelt@oregonmedicalresearch.com

¹ Oregon Medical Research Center, 9495 SW Locust St., Suite G, Portland, OR 97223, USA

² K Papp Clinical Research and Probity Medical Research, Waterloo, Canada

³ Dermatology Centre, Salford Royal Hospital, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK

⁴ Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

⁵ Medical Dermatology Specialists, Inc., Atlanta, GA, USA

⁶ Eli Lilly and Company, Indianapolis, IN, USA

⁷ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany